Skip to main content

Table 2 Clinical characteristics of 32 patients and their outcome

From: Treatment and outcome of 32 patients with distant metastases of Hürthle cell thyroid carcinoma: a single-institution experience

Patient number Age range at presentation Age range at metastases Tumor diameter (cm) pT-stage pN-stage M-stage Site of metastases Tg at diagnosis of metastases Survival Disease-free interval Survival from diagnosis of distant metastases Cause of death
1 85–89 85–89 7,5 3 0 1 L 7414 77 0 77 DDM
2 75–79 75–79 5 4b 0 1 L 4450 53 0 53 DOC
3 70–74 70–74 8 3 0 1 L 265 141 0 141 DDM
4 70–74 70–74 6 4a 0 1 B 183 13 0 13 DDM
5 65–69 65–69 8,5 3 0 1 L 16650 185 0 185 Alive
6 65–69 65–69 8 3 0 1 BL 4010 148 0 148 DDM
7 60–64 60–64 8 0 0 1 B No data 153 0 153 DDM
8 60–64 60–64 4,5 3 1b 1 L 62600 131 0 131 DDM
9 60–64 60–64 2 2 0 1 B 69 1 0 1 LFU
10 60–64 60–64 6,5 3 0 1 L 1300 72 0 72 DDM
11 55–59 55–59 5 4b 1b 1 L 190 201 0 201 DDM
12 45–49 45–49 9 4b 0 1 L 5800 52 0 52 DDM
13 85–89 85–89 12 3 0 0 Mediastinum 277 52 38 14 DDM
14 75–79 75–79 3 2 0 0 B 47 126 34 92 Alive
15 75–79 85–89 8 3 0 0 L 696 144 84 60 DDM
16 70–74 70–74 2 4a 1a 0 Kidney 1432 318 180 138 DDM
17 70–74 75–79 8 3 0 0 L 1300 63 36 2 DDLTP
18 70–74 80–84 6,8 3 0 0 L 1000 132 96 36 Alive
19 70–74 70–74 5,5 4a 0 0 L No data 26 3 23 DDM
20 65–69 65–69 3,6 3 0 0 L 0.1 46 43 3 Alive
21 65–69 70–74 7 4a 0 0 L No data 63 53 10 DDM
22 65–69 65–69 9 3 0 0 BL 1100 145 52 93 DDM
23 60–64 65–69 18 4b 1b 0 L 416 100 20 53 DDM
24 60–64 70–74 3 2 0 0 L, liver 501 121 84 36 DDM
25 60–64 65–69 4,5 3 0 0 L 30773 97 49 48 Alive
26 60–64 70–74 7 3 0 0 L 196 138 113 27 Alive
27 60–64 60–64 6,5 3 1a 0 B 763 43 16 27 Alive
28 60–64 60–64 8 4a 0 0 Mediastinum 1800 145 44 101 DDLTP
29 50–54 55–59 13 4b 0 0 L 800 75 26 42 DDM
30 50–54 75–79 6 3 0 0 L 163 337 31 65 DDM
31 50–54 50–54 3 2 1b 0 L Tg-antibodies 33 9 24 Alive
32 35–39 40–44 4 3 0 0 BL 108 286 60 226 Alive
  1. Legend: B bone, L lungs, DDM dead of distant metastases, DOC dead of other causes, LFU lost to follow-up, DDLTP dead of distant and locoregional tumor progression
\